文献速递乳腺癌

胚系BRCA突变与年轻起病乳腺癌的预后:POSH前瞻性队列研究

Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
PubMed 文献 · Lancet Oncol · 2018-01-11

POSH研究前瞻性纳入英国127家医院2733例40岁及以下浸润性乳腺癌患者,338例(12%)检出致病性BRCA突变。

要点

  • 年轻乳腺癌中BRCA突变携带者与非携带者总生存相似
  • 三阴性亚组BRCA携带者仅2年生存有优势,5年、10年无差异
  • 二次原发癌预防手术时机需结合首癌预后与患者意愿

核心结论

  • 年轻起病乳腺癌BRCA突变携带者与非携带者总生存相似。
  • 三阴性乳腺癌BRCA携带者可能在诊断后最初几年有生存优势。

研究设计与样本

  • 前瞻性队列研究,自英国127家医院招募40岁及以下首诊浸润性乳腺癌女性患者。

主要发现

  • 338例(12%)检出致病性BRCA突变,其中BRCA1 201例、BRCA2 137例。
  • 678例死亡中651例(96%)死于乳腺癌。

临床怎么用

  • 年轻乳腺癌患者BRCA状态不影响首癌总生存预期。
  • 三阴性BRCA携带者早期生存优势不持续,长期随访仍必要。
  • 决定降低二次原发癌风险的手术时机应结合首癌预后与患者偏好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Retrospective studies provide conflicting interpretations of the effect of inherited genetic factors on the prognosis of patients with breast cancer. The primary aim of this study was to determine the effect of a germline BRCA1 or BRCA2 mutation on breast cancer outcomes in patients with young-onset breast cancer. METHODS: We did a prospective cohort study of female patients recruited from 127 hospitals in the UK aged 40 years or younger at first diagnosis (by histological confirmation) of invasive breast cancer. Patients with a previous invasive malignancy (except non-melanomatous skin cancer) were excluded. Patients were identified within 12 months of initial diagnosis. BRCA1 and BRCA2 mutations were identified using blood DNA collected at recruitment. Clinicopathological data, and data regarding treatment and long-term outcomes, including date and site of disease recurrence, were collected from routine medical records at 6 months, 12 months, and then annually until death or loss to follow-up. The primary outcome was overall survival for all BRCA1 or BRCA2 mutation carriers (BRCA-positive) versus all non-carriers (BRCA-negative) at 2 years, 5 years, and 10 years after diagnosis. A prespecified subgroup analysis of overall survival was done in patients with triple-negative breast cancer. Recruitment was completed in 2008, and long-term follow-up is continuing. FINDINGS: Between Jan 24, 2000, and Jan 24, 2008, we recruited 2733 women. Genotyping detected a pathogenic BRCA mutation in 338 (12%) patients (201 with BRCA1, 137 with BRCA2). After a median follow-up of 8·2 years (IQR 6·0-9·9), 651 (96%) of 678 deaths were due to breast cancer. There was no significant difference in overall survival between BRCA-positive and BRCA-negative patients in multivariable analyses at any timepoint (at 2 years: 97·0% [95% CI 94·5-98·4] vs 96·6% [95·8-97·3]; at 5 years: 83·8% [79·3-87·5] vs 85·0% [83·5-86·4]; at 10 years: 73·4% [67·4-78·5] vs 70·1% [67·7-72·3]; hazard ratio [HR] 0·96 [95% CI 0·76-1·22]; p=0·76). Of 558 patients with triple-negative breast cancer, BRCA mutation carriers had better overall survival than non-carriers at 2 years (95% [95% CI 89-97] vs 91% [88-94]; HR 0·59 [95% CI 0·35-0·99]; p=0·047) but not 5 years (81% [73-87] vs 74% [70-78]; HR 1·13 [0·70-1·84]; p=0·62) or 10 years (72% [62-80] vs 69% [63-74]; HR 2·12 [0·82-5·49]; p= 0·12). INTERPRETATION: Patients with young-onset breast cancer who carry a BRCA mutation have similar survival as non-carriers. However, BRCA mutation carriers with triple-negative breast cancer might have a survival advantage during the first few years after diagnosis compared with non-carriers. Decisions about timing of additional surgery aimed at reducing future second primary-cancer risks should take into account patient prognosis associated with the first malignancy and patient preferences. FUNDING: Cancer Research UK, the UK National Cancer Research Network, the Wessex Cancer Trust, Breast Cancer Now, and the PPP Healthcare Medical Trust Grant.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Copson ER, Maishman TC, Tapper WJ, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018. PMID: 29337092. doi:10.1016/S1470-2045(17)30891-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。